Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
Acasti Pharma Inc. (NASDAQ: ACST) will host a conference call on February 14, 2023, at 1:00 PM ET to discuss its third-quarter financial results for the period ending December 31, 2022, and provide updates on corporate progress. The conference call can be accessed via telephone or webcast. Acasti is focused on developing clinical-stage drug candidates for rare diseases, with three lead assets, GTX-104, GTX-102, and GTX-101, each receiving Orphan Drug Designation from the FDA. This designation provides seven years of marketing exclusivity post-launch in the U.S. Acasti holds over 40 granted and pending patents for its drug delivery technologies.
- Acasti's lead clinical assets granted Orphan Drug Designation by the FDA provide seven years of marketing exclusivity.
- The company holds over 40 granted and pending patents for its innovative drug delivery technologies.
- None.
Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time
LAVAL, QB, Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, February 14, 2023, to discuss the Company's corporate progress and other developments, as well as financial results for third quarter 2023 ended December 31, 2022.
The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webcast of the call may be accessed at https://app.webinar.net/E7mea0O2qxk or on the Company's Investor Relations section of the website: https://www.acastipharma.com/investors/.
A webcast replay will be available on the Company's Investors News/Events section of the website (https://www.acastipharma.com/investors/) through February 14, 2023. A telephone replay of the call will be available approximately one hour following the call, through February 21, 2023, and can be accessed by dialing 877-344-7529 for U.S. callers or +1 412-317-0088 for international callers and entering replay access code: 9403168.
About Acasti
Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes. Acasti's three lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provide the assets with seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily affects children, causing severe disability, and for which no treatment currently exists; and (iii) GTX-101, a topical spray targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.
For more information, please visit: https://www.acastipharma.com/en.
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking information" within the meaning of Canadian securities laws and "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, "forward looking statements"). Such forward looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms "believes," "belief," "expects," "intends," "anticipates," "potential," "should," "may," "will," "plans," "continue", "targeted" or other similar expressions to be uncertain and forward looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release are based upon Acasti's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. All forward-looking statements contained in this press release speak only as of the date on which they were made. Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws. Neither NASDAQ, the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Acasti Contact:
Jan D'Alvise
Chief Executive Officer
Tel: 450-686-4555
Email: info@acastipharma.com
www.acastipharma.com
Investor Contact:
Lytham Partners, LLC
Tel: 602-889-9700
Email: acst@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/acasti-pharma-to-report-third-quarter-2023-financial-results-on-tuesday-february-14-2023-301740215.html
SOURCE Acasti Pharma Inc.
FAQ
When is Acasti's financial results call for Q3 2023?
What are the key drug candidates Acasti is developing?
What designation has Acasti received from the FDA for its drug candidates?
How can I access Acasti's conference call?
What is the focus of Acasti Pharma?
